title: Enhanced late na(+) currents in atrial fibrillation new drug target or just an epiphenomenon?
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schotten
authors.forename: Sander
authors.initials: S
authors.lastname: Verheule
authors.forename: Benoit-Gilles
authors.initials: BG
authors.lastname: Kerfant
authors.forename: Maura
authors.initials: M
authors.lastname: Greiser
mesh_terms: D000083:Acetanilides / Q000494:pharmacology* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy; D002478:Cells, Cultured; D016503:Drug Delivery Systems; D005260:Female; D006325:Heart Atria / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D000069458:Ranolazine; D018570:Risk Assessment; D012494:Sampling Studies; D012680:Sensitivity and Specificity; D015222:Sodium Channels / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000083:Acetanilides; D000889:Anti-Arrhythmia Agents; D010879:Piperazines; D015222:Sodium Channels; D000069458:Ranolazine